
FOR DEBATE

Age, influenza pandemics and disease dynamics

A. L. GREER^{1,4}, A. TUIE¹ AND D. N. FISMAN^{1,2,3*}

¹ Dalla Lana School of Public Health, ² Department of Health Policy, Management, and Evaluation, and ³ Department of Medicine, University of Toronto, Toronto, ON, Canada

⁴ Public Health Agency of Canada, Ottawa, ON, Canada

(Accepted 17 February 2010; first published online 22 March 2010)

SUMMARY

The world is currently confronting the first influenza pandemic of the 21st century [caused by a novel pandemic influenza A (H1N1) virus]. Earlier pandemics have been characterized by age distributions that are distinct from those observed with seasonal influenza epidemics, with higher attack rates (and correspondingly increased proportionate or relative mortality) in younger individuals. While the genesis of protection against infection in older individuals during a pandemic is uncertain, differential vulnerability to infection by age has important implications for disease dynamics and control, and for choice of optimal vaccination strategies. Age-related vulnerability to infection may explain differences between school- and community-derived estimates of the reproductive number (R) for a newly emerged pandemic strain, and may also help explain the failure of a newly emerged influenza A (H1N1) virus strain to cause a pandemic in 1977. Age-related factors may also help explain variability in attack rates, and the size and impact of influenza epidemics across jurisdictions and between populations. In Canada, such effects have been observed in the apparently increased severity of outbreaks on Indigenous peoples' reserves. The implications of these patterns for vaccine allocation necessitate targeted research to understand age-related vulnerabilities early in an influenza pandemic.

Key words: Epidemiology, infectious disease dynamics, influenza, mathematical modelling.

INTRODUCTION

A pandemic influenza A (H1N1) virus emerged in Mexico in March 2009 and has subsequently spread rapidly around the world [1]. The World Health Organization affirmed the existence of the first influenza pandemic of the 21st century on 11 June 2009. As with earlier pandemic influenza strains in 1918, 1957 and 1968 [2–6], and as with the 'Russian flu'

H1N1 outbreak in the late 1970s [7], the 2009 pandemic H1N1 influenza A virus has been associated with higher attack rates in younger individuals [8, 9], and most early fatalities appear to have occurred in individuals aged < 50 years [1] (Fig. 1). This stands in marked contrast to mortality patterns observed during seasonal influenza epidemics, where mortality is seen predominantly in those at the extremes of age [10].

This unique pattern means that optimal pandemic response strategies will differ from the well-tested strategies used for seasonal influenza and therefore, it is critical that we consider the following questions: What are the implications of differential age-related

* Author for correspondence: D. N. Fisman, MD, MPH, FRCPC, Dalla Lana School of Public Health, 155 College Street, Room 678, Toronto, Ontario, Canada M5T 3M7.
(Email: david.fisman@utoronto.ca)




Fig. 1. Age distribution of pandemic influenza A (H1N1) virus cases in Ontario, Canada. The histograms show the proportion of cases, by age, in individuals testing positive for pandemic influenza A (H1N1) virus in the Ontario Public Health Laboratory system. Risk of infection decreases with age, and is rare in individuals born prior to 1957.

susceptibility for the dynamics of influenza epidemics associated with newly emerged strains? Why do pandemics cause a ‘W-shaped’ pattern of excess relative or absolute mortality? How can these dynamics help explain the geographic variability in the apparent severity of influenza pandemics? How do these dynamics influence the choice of disease mitigation and control strategies? In the following sections we will address each of these questions in the context of pandemic H1N1 influenza A (H1N1) virus (pH1N1).

Disease dynamics and W-shaped mortality curves

The basic reproductive number of an infectious disease (R_0) can be described as the number of new cases created by a single infected individual in a fully susceptible population. As an example, when $R_0 = 3$, each infected individual typically generates three secondary cases before they recover and each of these secondary cases go on to create three additional cases. When R_0 is > 1 , the disease can spread easily throughout the population, causing an epidemic [11]. However, R_0 is an idealized quantity, and represents the reproductive number of an infectious disease introduced into a completely susceptible population in the absence of intervention (e.g. no attempt to keep infectious individuals from interacting with susceptible individuals via isolation). When these conditions do not apply, the reproductive number is often denoted ‘effective R ’, or R_e . As more individuals begin to acquire

immunity (as a result of previous infection), the reproductive number changes from R_0 to a smaller R_e because each new case can no longer generate three new secondary cases due to immunity in the population. The relationship between R_0 and R_e in a homogeneously mixed population is simply:

$$R_e = R_0 \times S, \quad (1)$$

where S is the fraction of the population susceptible to the infectious disease in question.

The distinction between R_0 and R_e makes it possible to reconcile the varying estimates of R that have been derived for pH1N1. For example, Paterson and colleagues investigated an outbreak of pH1N1 at the St Francis Preparatory School in New York early in the 2009 pandemic. Their analysis of the outbreak yielded a reproductive number of 2.7 in that particular school setting [12]. They noted that another recent estimate of the reproductive number in the community setting, based on events in Mexico in April 2009, was lower (~ 1.5) [13]; we have recently published similar estimates of community-based reproductive numbers for pH1N1 in the Canadian province of Ontario [14].

Elevated reproductive numbers in school settings could be related to crowding or behavioural factors. However, if notwithstanding the novel nature of pH1N1, older individuals in the population are partially protected against infection by prior exposure to antigenically similar viruses, then the reproductive number estimated in a young population (i.e. in a school outbreak) should approximate R_0 (the reproductive number in an entirely susceptible population) whereas the R estimated by Fraser and colleagues would simply be R_e in a partially susceptible population. Protection in older individuals is consistent with the young age of cases reported in Mexico, USA, Canada, and Japan [15, 16]. Younger age distributions of cases were also noted in the 1918, 1957 and 1968 influenza pandemics [2, 5, 8, 9], and have been attributed to early-life exposure to related influenza strains in older individuals [8].

Returning to R_0 and R_e in a well-mixed population, we can use simple algebra to show that

$$S = R_e / R_0, \quad (2)$$

If $R_0 = 2.7$, and $R_e = 1.5$, then R_e / R_0 in this case would be ~ 0.55 . It is interesting to note that $\sim 55\%$ of the USA population is aged < 40 years [17]. We recently demonstrated that individuals aged > 40 years appear

protected against infection with pH1N1 [18]. Older individuals may have prior exposure to H1N1 influenza strains that circulated each year prior to the 1957 pandemic. Both epidemiological and serological data derived from the current pandemic suggest that individuals born prior to 1957 have a high degree of protection against infection with pH1N1, and those born between 1957 and 1976 appear to have a degree of protection as well [18, 19].

Extending this concept provides an obvious hypothesis regarding the non-emergence of a H1N1 pandemic in 1976–1977. As a disease with an initial $R_e < 1$ cannot cause an epidemic following introduction, increasing the proportion of individuals in a given population who have pre-existing age-related immunity to a novel influenza strain decreases the likelihood of pandemic occurrence. The failure of the Russian flu H1N1 influenza strain that emerged in 1977 to cause a pandemic may have, again, reflected population exposure to similar H1N1 strains that were circulating prior to 1957 [7]. However, in this situation, a much higher proportion of the population (all individuals aged >20 years) would have had extensive prior exposure to H1N1, driving down S . During the Russian flu episode, attack rates $>70\%$ were observed in many high schools and military bases within the USA, but very few cases were observed in teachers, faculty members or staff making ‘Russian flu’ an epidemic only in the young, and not a true pandemic [7].

The atypical pattern of mortality associated with some pandemics, with elevated relative or absolute risk in individuals in the middle years of life, has been described as ‘W-shaped’, to denote the appearance of histograms of fatalities by age [4]. Such a pattern emerged in the 2009 pandemic [1, 20] and was famously associated with the 1918 influenza pandemic [4]. However, such a pattern was also present in the 1957 pandemic when relative, rather than absolute, risk of mortality is considered (i.e. the increase in pneumonia and influenza-related mortality in younger individuals relative to that seen in the preceding influenza season was far greater than that seen in older individuals [3]). Limited data suggest that W-shaped relative mortality patterns may have existed during the presumed 1837 influenza pandemic as well [21].

The signature W-shaped mortality identified in influenza pandemics may be seen entirely as a result of differences in age-related risk of infection, without the need to invoke differences in age-specific risk of




Fig. 2. Schematic diagram of derivation of W-shaped mortality patterns. Attack rate (—) diminishes with age, while case-fatality rate (---) exhibits a U shape (highest at extremes of age). The resultant distribution of deaths (—) has a W shape, characteristic of influenza pandemics.

poor outcome between seasonal and pandemic strains. In other words, it is not necessary to invoke the presence of a superantigen response in a subset of otherwise healthy young adults [22] in order to make sense of W-shaped mortality. This concept is illustrated graphically in the schematic diagram presented as Figure 2. It can be seen that when a disease process that is associated with U-shaped case-fatality, such as seasonal influenza (which has highest case-fatality rates in the youngest and oldest individuals) occurs with attack rates that diminish with age (as is characteristic of pandemic influenza), the result is a W-shaped distribution of mortality by age.

It may be surprising that a temporally distant influenza virus exposure would confer protection, when little durable immunity is conferred by seasonal exposure to closely related influenza strains as a result of antigenic drift [23]. However, this effect may be consistent with the immunological model of ‘original antigenic sin’ [24–26], which suggests that the first exposure to an antigen provokes a strong humoral immune response; as influenza antigens drift over time, neutralizing antibodies become less effective, but re-challenge provokes expansion of the original B-memory response. A recent study evaluating banked sera from prior to the onset of the current pandemic has identified a high prevalence of cross-reactive neutralizing antibody to pH1N1 in older individuals, particularly those aged >60 years [19].

In this instance, it might be expected that pandemic H1N1 haemagglutinin (HA1) genes would bear similarity to those of influenza A strains circulating prior to 1957. Preliminary evaluations of archived HA1 sequences in Genbank [27] do not suggest a close relationship between pH1N1 and pre-1957 H1N1 strains, but the complexity of such comparisons and gaps in knowledge of pre-1957 viral sequences suggest that this hypothesis warrants further investigation.

Implications for populations with low mean age

Increased susceptibility to pH1N1 infection in younger individuals, relative to older adults, would have several important epidemiological implications: it suggests that schools, universities, military bases, and other areas with large concentrations of younger individuals will be major foci for pandemic influenza outbreaks. Similarly, it means that optimal vaccination strategies target younger adults than are usually targeted in seasonal influenza vaccination campaigns [9]; and it means that low-income countries or specific segments of the population, which have ‘triangular’ population distributions (younger individuals greatly in excess of older individuals) will have attack rates higher than seen in countries with larger proportions of older individuals.

In Canada, Indigenous populations have been severely impacted by the introduction and spread of pH1N1 in isolated communities [28, 29]. Although this severity has been attributed to crowding and high rates of underlying illness in Indigenous communities [28–30], and could also reflect differential functioning of surveillance systems in different communities, a striking feature of these communities is that the age distribution of community members tends to be younger than the general Canadian population. In contrast to the general Canadian population where ~43% of the population are aged <34 years and 26% are aged >52 years, 60% of Indigenous communities are aged <34 years and only ~14% are aged >52 years [31]. We recently published data from Ontario demonstrating that the relative risk of infection with pH1N1 is ~0.42 in individuals aged 33–52 years (i.e. those born between the 1957 and 1968 pandemics), and 0.15 in individuals aged ≥53 years (i.e. those born prior to the 1957 pandemic) [18].

If we assume that the risk of exposure sufficient to transmit infection (P_{exp}) does not vary across age groups then we can estimate a crude relative risk for

Canadian Indigenous communities, relative to the Canadian population as a whole as follows, using the age distributions and relative risks described above:

$$\begin{aligned} \text{RR}_{\text{FN}} &= \text{Risk}_{\text{FN}} / \text{Risk}_{\text{Can}} \\ &= \frac{(P_{\text{exp}} \times 1 \times 0.6 + P_{\text{exp}} \times 0.42 \times 0.26 + P_{\text{exp}} \times 0.15 \times 0.14)}{(P_{\text{exp}} \times 1 \times 0.43 + P_{\text{exp}} \times 0.42 \times 0.29 + P_{\text{exp}} \times 0.15 \times 0.26)} \\ &= \frac{(1 \times 0.6 + 0.42 \times 0.26 + 0.15 \times 0.14)}{(1 \times 0.43 + 0.42 \times 0.29 + 0.15 \times 0.26)} \\ &= 0.73 / 0.59, \\ &= 1.24. \end{aligned}$$

In other words, although poverty and associated crowding could result in higher attack rates in Indigenous populations in Canada, we would expect the risk of infection to be 24% higher in Indigenous Canadians than in other Canadians on the basis of *age distribution alone*, with the attributable risk percent for infection in Indigenous Canadians being equal to 19%. However, the relative risk of infection in some Indigenous communities during the first wave of the 2009 influenza pandemic appeared many times higher than that seen in the general Canadian population [29]. How can these differences be reconciled?

To understand that these observations are not inconsistent, it is important to recall that epidemics are dynamic, time-dependent processes, with risk of infection for individuals evolving over the course of an epidemic. We can capture the dynamic character of an epidemic by representing it in terms of reproductive numbers. Assume there is universal susceptibility to novel pH1N1 in young individuals, and universal exposure to pH1N1. In that case, the proportion of the population susceptible (S) to infection in Canada’s Indigenous peoples would be Risk_{FN} of 0.73. Assuming that the R_0 is truly 2.7, and using equation (1), we can estimate that R_e in this population would be 0.73×2.7 , or 2.0; the corresponding value for R_e in the general Canadian population would be 1.6.

Figure 3 shows simulated epidemic curves and cumulative attack rates associated with infections with $R=2.0$ and $R=1.6$, respectively. It can be seen that the simulated epidemic curve for the Indigenous population peaks earlier and has a narrower base than that for the general Canadian population. The ratio of cumulative attack rates (i.e. cumulative attack rate in the Indigenous community divided by the cumulative attack rate in the general population) at any point in time will be the estimated relative risk of infection available to public health practitioners at that point in time. In Figure 4, these ratios are plotted (on




Fig. 3. The impact of reproductive number on the shape and timing of the epidemic curve, and final epidemic size. With a slightly higher R (1.9, ---), the epidemic grows more quickly, peaks earlier, and ends earlier, with a higher cumulative attack rate. An epidemic with $R=1.5$ (—) is shown for comparison.

a log scale) over time; because of the earlier peak of the epidemic in the younger (Indigenous) population the relative risk in this population is extremely high (~ 40); as the epidemic wanes in this population, and takes off in the general population, the relative risk declines. The relative risk of infection at the end of the epidemic is simply the ratio of final epidemic sizes derived using the Kermack–McKendrick ‘final size formula’ [32], which in this case is $0.79/0.64$, or 1.23 , almost identical to the relative risk estimated using age-weighted estimates of risk and much smaller than the relative risk estimates derived by taking ratios of attack rates early on.

The key, however, is that in younger populations, the epidemic takes a more rapid course with an earlier peak, which may have the practical effects of overwhelming public health and hospital resources, causing concern or panic in the population, and/or occurring entirely before implementation of programmes aimed at mitigation of the epidemic (e.g. vaccine programmes) can be put into place. This phenomenon will apply in any population with the ‘triangular’ age distribution characteristic of lower-income regions and countries, and may help explain some of the apparent geographic variation in severity characteristic of influenza pandemics [6].

Optimal disease mitigation and control

Seasonal influenza vaccination campaigns typically target the elderly and those of any age with one or




Fig. 4. Changing estimates of relative risk of infection in younger population in an epidemic. The curve represents the ratio of the cumulative attack rates over time presented in Figure 2. The earlier epidemic peak in the younger population results in an extremely high relative risk of infection early in the epidemic. The relative risk of infection when the epidemic ends is the ratio of the final epidemic sizes in the two populations (relative risk ~ 1.25).

more chronic medical conditions, to protect those most at risk of complications from infection. The different relationship between age and disease risk in seasonal influenza epidemics [33, 34] compared to influenza pandemics [8, 9, 35] means that seasonal vaccination frameworks are not likely to be applicable in a pandemic situation. Miller and colleagues have pointed out that if the goal of vaccination in a pandemic is to minimize life-years lost, strategies need to be ‘pandemic-specific’, and reflect the age distribution of cases [9]. (Of note, Galvani and colleagues have also pointed out that because of their relative mobility and high rates of contact with others, vaccine strategies targeting younger individuals at diminished risk of poor outcomes may actually be optimal in seasonal influenza as well [36].)

In the face of a higher force of infection in younger persons with the currently circulating pandemic strain, the apparent protection against infection in older adults, and the expectation that initial vaccine supplies were expected to be insufficient to vaccinate the entire population, many jurisdictions have implemented alternate vaccination strategies that reflected age-related changes in susceptibility to infection [37, 38]. The WHO pH1N1 vaccine allocation guidelines also reflected the observed pH1N1 age-infection risk distribution, with younger adults recommended for prioritization for vaccine receipt over older adults [39]. Focusing initial vaccination efforts

on children and younger adults was adopted as a means of effectively targeting the groups with the highest expected disease burden, as well as those most responsible for disease transmission [40]. The effectiveness of these alternative vaccination schemes in reducing the population-level impact of pH1N1 remains to be determined, although the delayed availability of vaccine in the northern hemisphere, relative to the peak of pH1N1 activity probably reduced the utility of vaccination in general as a disease mitigation tool [41].

In the absence of vaccine or other pharmaceutical interventions (i.e. antiviral treatment or prophylaxis), social distancing measures, including school closures and cancellation of large public gatherings, are an effective strategy for controlling influenza transmission [42, 43]. Models suggest that school closures would act synergistically with other control interventions [44]. Closures were implemented in Mexico and other jurisdictions early in the pandemic [45, 46], but school closures were not widely adopted due to their high economic costs and disruptive nature.

Finally, as might be expected given pH1N1's propensity to spread in susceptible populations, summer camps, which have large groups of children and young adults in close contact, were also observed to be hotspots for pH1N1 [47]. In the northern hemisphere, continued spread of pH1N1 during the summer months, when influenza activity generally declines, was a surprising phenomenon. Seasonal oscillation has resulted in an apparent increase in R_0 for pH1N1 in North America in autumn 2009 [23], a phenomenon that could be related to either environmental or social phenomena (e.g. reopening of schools and universities closed during the summer).

CONCLUSION

As with previous pandemics, the 2009 emergence of pH1N1 strain has been associated with age-related risks of infection that are distinct from those seen during seasonal influenza epidemics. The dynamics of disease transmission and corresponding public-health planning priorities and intervention strategies will differ depending on the age distribution of cases. As such, we echo the recommendations of Miller and colleagues, who note that rapid assessment of the relationship between age and infection risk needs to be a high priority for research with the emergence of an influenza strain with pandemic potential [9]. More broadly, however, the contrast between age effects in

influenza pandemics relative to those seen in seasonal epidemics, may be an important clue into the evolution, dynamics, emergence, and apparent disappearance of influenza strains over time.

DECLARATION OF INTEREST

Dr Fisman has previously received unrestricted research funds from Sanofi-Pasteur Canada, which manufactures influenza vaccines.

REFERENCES

1. **Chowell G, et al.** Severe respiratory disease concurrent with the circulation of H1N1 influenza. *New England Journal of Medicine* 2009; **361**: 674–679.
2. **Henderson DA, et al.** Public health and medical responses to the 1957–58 influenza pandemic. *Biosecurity & Bioterrorism* 2009; **7**: 265–273.
3. **Serfling RE, Sherman IL, Houseworth WJ.** Excess pneumonia-influenza mortality by age and sex in three major influenza A2 epidemics, United States, 1957–58, 1960 and 1963. *American Journal of Epidemiology* 1967; **86**: 433–441.
4. **Olson DR, et al.** Epidemiological evidence of an early wave of the 1918 influenza pandemic in New York City. *Proceedings of the National Academy of Sciences USA* 2005; **102**: 11059–11063.
5. **Stuart-Harris CH.** Control of influenza: lack of knowledge versus lack of application of knowledge. *Archives of Environmental Health* 1970; **21**: 276–285.
6. **Miller MA, et al.** The signature features of influenza pandemics – implications for policy. *New England Journal of Medicine* 2009; **360**: 2595–2598.
7. **Gregg M, Hinman A, Craven RB.** The Russian flu. Its history and implications for this year's influenza season. *Journal of the American Medical Association* 1978; **240**: 2260–2263.
8. **Ahmed R, Oldstone M, Palese P.** Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. *Nature Immunology* 2007; **8**: 1188–1193.
9. **Miller M, et al.** Prioritization of influenza pandemic vaccination to minimize years of life lost. *Journal of Infectious Diseases* 2008; **198**: 305–311.
10. **Dushoff J, et al.** Mortality due to influenza in the United States – an annualized regression approach using multiple-cause mortality data. *American Journal of Epidemiology* 2006; **163**: 181–187.
11. **Fisman D.** Modelling an influenza pandemic: a guide for the perplexed. *Canadian Medical Association Journal* 2009; **181**: 171–173.
12. **Paterson B, Durrheim DN, Tuyl F.** Influenza: H1N1 goes to school. *Science* 2009; **325**: 1071–1072.

13. **Fraser C, et al.** Pandemic potential of a strain of influenza A (H1N1): early findings. *Science* 2009; **324**: 1557–1561.
14. **Tuite AR, et al.** Estimated epidemiologic parameters and morbidity associated with pandemic H1N1 influenza. *Canadian Medical Association Journal* 2009; **182**: 131–136.
15. **CDC.** Novel influenza A (H1N1) virus infections – worldwide. *Morbidity and Mortality Weekly Report* 2009; **58**: 453–458.
16. **Normile D.** H1N1 rocks Japan, but WHO says it's still no pandemic. *Science Insider*, 2009 (<http://news.sciencemag.org/scienceinsider/2009/05/h1n1-rocks-japa.html>). Accessed 6 March 2010.
17. **U.S. Census Bureau.** Population estimates (<http://www.census.gov/popest/estimates.html>). Washington, DC: United States Government, 2009. Accessed 4 January 2010.
18. **Fisman D, et al.** Older age and reduced likelihood of infection with swine-origin influenza A H1N1. *New England Journal of Medicine* 2009; **361**: 2000–2001.
19. **Hancock K, et al.** Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. *New England Journal of Medicine* 2009; **361**: 1945–1952.
20. **Donaldson LJ, et al.** Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. *British Medical Journal* 2009; **339**: b5213.
21. **Streeten RJN.** Epidemic catarrh of 1836–37. In: Thompson T, ed. *Annals of Influenza or Epidemic Catarrhal Fever in Great Britain from 1510 to 1837*, 1st edn. London: New Sydenham Society, 1852, pp. 292–342.
22. **Kash JC, et al.** Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. *Nature* 2006; **443**: 578–581.
23. **Dushoff J, et al.** Dynamical resonance can account for seasonality of influenza epidemics. *Proceedings of the National Academy of Sciences USA* 2004; **101**: 16915–16916.
24. **Francis T.** On the doctrine of original antigenic sin. *Proceedings of the American Philosophical Society* 1960; **104**: 572–578.
25. **Krause R.** The swine flu episode and the fog of epidemics. *Emerging Infectious Diseases* 2006; **12**: 40–43.
26. **Taber LH, et al.** Infection with influenza A-Victoria virus in Houston families, 1976. *Journal of Hygiene* 1981; **86**: 303–313.
27. **National Center for Biotechnology Information.** Influenza virus resource: information, search, and analysis (<http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html>). Bethesda, MD: National Library of Medicine, National Institutes of Health, 2009. Accessed 4 January 2010.
28. **Kumar A, et al.** Critically ill patients with 2009 influenza A(H1N1) infection in Canada. *Journal of the American Medical Association* 2009; **302**: 1872–1879.
29. **La Ruche G, et al.** The 2009 pandemic H1N1 influenza and indigenous populations of the Americas and the Pacific. *Eurosurveillance* 2009; **14**(42).
30. **CDC.** Deaths related to 2009 pandemic influenza A (H1N1) among American Indian/Alaska Natives – 12 states, 2009 (<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5848a1.htm>). Accessed 12 December 2009. *Morbidity and Mortality Weekly Report* 2009; **58**: 1341–1344.
31. **Health Canada.** A statistical profile on the health of First Nations in Canada. (http://www.hc-sc.gc.ca/fnihah-spnia/alt_formats/fnihb-dgspni/pdf/pubs/aborig-autoch/2009-stats-profil-eng.pdf). Accessed 17 December 2009. Ottawa, Ontario: Health Canada; 2009. Report No.: HC Pub: 3555.
32. **Pascual M, et al.** Malaria resurgence in the East African highlands: temperature trends revisited. *Proceedings of the National Academy of Sciences USA* 2006; **103**: 5829–5834.
33. **Louie JK, et al.** Severe pediatric influenza in California, 2003–2005: implications for immunization recommendations. *Pediatrics* 2006; **117**: e610–8.
34. **Simonsen L, et al.** The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. *Molecular Biology and Evolution* 2007; **24**: 1811–1820.
35. **Luk J, Gross P, Thompson W.** Observations on mortality during the 1918 influenza pandemic. *Clinical Infectious Diseases* 2001; **33**: 1375–1378.
36. **Galvani AP, Reluga TC, Chapman GB.** Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum. *Proceedings of the National Academy of Sciences USA* 2007; **104**: 5692–5697.
37. **Public Health Agency of Canada.** Guidance on H1N1 flu vaccine sequencing (<http://www.phac-aspc.gc.ca/alert-alerte/h1n1/vacc/vacc-eng.php>). Accessed 1 January 2010. Ottawa, Canada: Government of Canada, 2009.
38. **CDC.** Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. *Morbidity and Mortality Weekly Report (Recommended Reports)* 2009; **58**: 1–8.
39. **WHO.** Pandemic (H1N1) 2009 briefing note 2: WHO recommendations on pandemic (H1N1) 2009 vaccines. (http://www.who.int/csr/disease/swineflu/notes/h1n1_vaccine_20090713/en/index.html). Accessed 5 January 2010. Geneva: World Health Organization, 2009.
40. **Smith S, et al.** Vaccines for preventing influenza in healthy children. *Cochrane Database of Systematic Reviews* 2006. Issue 1. Article No. CD004879.
41. **Tuite AR, et al.** Optimal pandemic influenza vaccine allocation strategies for the Canadian population. Version 10 (<http://knol.google.com/k/ashleigh-tuite/optimal-pandemic-influenza-vaccine/66mlsbkz358/2>). Accessed 8 January 2010. *PLoS Currents: Influenza*, 2010.
42. **Bootsma M, Ferguson N.** The effect of public health measures on the 1918 influenza pandemic in U.S. cities. *Proceedings of the National Academy of Sciences USA* 2007; **104**: 7588–7593.

43. **Hatchett R, Mecher C, Lipsitch M.** Public health interventions and epidemic intensity during the 1918 influenza pandemic. *Proceedings of the National Academy of Sciences USA* 2007; **104**: 7582–7587.
44. **Gojovic MZ, et al.** Modelling mitigation strategies for pandemic (H1N1) 2009. *Canadian Medical Association Journal* 2009; **181**: 673–680.
45. **CDC.** Update: novel influenza A (H1N1) virus infection – Mexico, March–May 2009. *Morbidity and Mortality Weekly Report* 2009; **58**: 585–589.
46. **Shetty P.** Putting influenza A H1N1 in its place. *Lancet Infectious Diseases* 2009; **9**: 331.
47. **Lewin T.** Summer camp '09: a swim, a cough, a quarantine. *The New York Times*, 23 July 2009.